Login to Your Account



BBA: Without overall growth, biosimilars market not sustainable

By Nuala Moran
Staff Writer

Friday, September 23, 2016

LONDON – The biosimilar version of infliximab has overtaken the originator product Remicade in the U.K., but in spite of lower prices, patient access to the anti-TNF-alpha antibody has not increased, according to the British Biosimilars Association (BBA).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription